From Algorithms to Cures: AI's Impact on Drug Discovery
DOI:
https://doi.org/10.70356/josapen.v1i2.12Keywords:
Artificial Intelligence (AI), Drug Development, Data-driven Methodologies, Therapeutic InterventionsAbstract
This study explores the paradigm-shifting fusion of artificial intelligence (AI) and pharmaceuticals, heralding a new era of innovation in drug development. AI's transformative potential revolutionizes the traditionally arduous drug discovery process by seamlessly assimilating vast data volumes encompassing molecular structures, genetics, and disease pathways. This synergy expedites the identification of potential drug candidates with heightened precision and efficiency, propelling breakthrough treatments. The exploration navigates through AI-driven computational models, showcasing their role in expediting drug validation and optimization. AI's iterative learning enhances predictive capabilities, forecasting medication efficacy and safety profiles, thereby minimizing clinical trial risks and boosting success rates. Beyond acceleration, AI reshapes drug development strategies toward personalized medicine. Analyzing expansive patient datasets, AI tailors treatments based on genetic variations and disease characteristics, promising optimized therapeutic outcomes and minimized adverse effects, marking a departure from traditional healthcare approaches. The methodology employed various research techniques, including literature reviews, data collection, surveys, case studies, synthesis, and recommendations, offering comprehensive insights into AI's impact on drug discovery. In conclusion, the study emphasized AI's transformative potential in revolutionizing drug discovery, advocating for continued exploration and integration to optimize pharmaceutical research and development practices.
Downloads
References
R. Qureshi et al., “AI in drug discovery and its clinical relevance,” Heliyon, vol. 9, no. 7, p. e17575, 2023, doi: 10.1016/j.heliyon.2023.e17575.
J. Yoo, T. Y. Kim, I. S. Joung, and S. O. Song, “Industrializing AI/ML during the end-to-end drug discovery process,” Curr. Opin. Struct. Biol., vol. 79, p. 102528, 2023, doi: 10.1016/j.sbi.2023.102528.
D. Vemula, P. Jayasurya, V. Sushmitha, Y. N. Kumar, and V. Bhandari, “CADD, AI and ML in drug discovery: A comprehensive review,” Eur. J. Pharm. Sci., vol. 181, no. October 2022, p. 106324, 2023, doi: 10.1016/j.ejps.2022.106324.
S. Yang and S. Kar, “Application of artificial intelligence and machine learning in early detection of adverse drug reactions (ADRs) and drug-induced toxicity,” Artif. Intell. Chem., vol. 1, no. 2, p. 100011, 2023, doi: 10.1016/j.aichem.2023.100011.
S. Bhattacharya, R. K. Mahato, S. Singh, G. K. Bhatti, S. S. Mastana, and J. S. Bhatti, “Advances and challenges in thyroid cancer: The interplay of genetic modulators, targeted therapies, and AI-driven approaches,” Life Sci., vol. 332, no. July, p. 122110, 2023, doi: 10.1016/j.lfs.2023.122110.
M. Gorostiola González, A. P. A. Janssen, A. P. IJzerman, L. H. Heitman, and G. J. P. van Westen, “Oncological drug discovery: AI meets structure-based computational research,” Drug Discov. Today, vol. 27, no. 6, pp. 1661–1670, 2022, doi: 10.1016/j.drudis.2022.03.005.
E. Vitali et al., “GPU-optimized Approaches to Molecular Docking-based Virtual Screening in Drug Discovery: A Comparative Analysis,” J. Parallel Distrib. Comput., vol. 186, no. December 2023, p. 104819, 2022, doi: 10.1016/j.jpdc.2023.104819.
X. Pan et al., “AI-DrugNet: A network-based deep learning model for drug repurposing and combination therapy in neurological disorders,” Comput. Struct. Biotechnol. J., vol. 21, pp. 1533–1542, 2023, doi: 10.1016/j.csbj.2023.02.004.
J. T. Moreira-Filho et al., “Artificial intelligence systems for the design of magic shotgun drugs,” Artif. Intell. Life Sci., vol. 3, no. September 2022, 2023, doi: 10.1016/j.ailsci.2022.100055.
A. V. Singh et al., “Integrative toxicogenomics: Advancing precision medicine and toxicology through artificial intelligence and OMICs technology,” Biomed. Pharmacother., vol. 163, p. 114784, 2023, doi: 10.1016/j.biopha.2023.114784.
A. Occhipinti, S. Verma, L. M. T. Doan, and C. Angione, “Mechanism-aware and multimodal AI: beyond model-agnostic interpretation.,” Trends Cell Biol., pp. 1–5, 2023, doi: 10.1016/j.tcb.2023.11.002.
D. O’Reilly, J. McGrath, and I. Martin-Loeches, “Optimizing artificial intelligence in sepsis management: Opportunities in the present and looking closely to the future,” J. Intensive Med., no. September, 2023, doi: 10.1016/j.jointm.2023.10.001.
T. Krishnamurti, K. Allen, L. Hayani, S. Rodriguez, and A. L. Davis, “Identification of maternal depression risk from natural language collected in a mobile health app,” Procedia Comput. Sci., vol. 206, pp. 132–140, 2022, doi: 10.1016/j.procs.2022.09.092.
S. Q. Guo et al., “AI protein structure prediction-based modeling and mutagenesis of a protostome receptor and peptide ligands reveal key residues for their interaction,” J. Biol. Chem., vol. 298, no. 10, pp. 1–16, 2022, doi: 10.1016/j.jbc.2022.102440.
F. Di Martino, F. Delmastro, and C. Dolciotti, “Explainable AI for malnutrition risk prediction from m-Health and clinical data,” Smart Heal., vol. 30, no. September, p. 100429, 2023, doi: 10.1016/j.smhl.2023.100429.
M. Yeganeh, M. H. Rezvani, and S. M. Laribaghal, “Jo ur n Pr pr oo,” Colloids Surfaces A Physicochem. Eng. Asp., p. 127120, 2021, doi: 10.1016/j.ncrops.2023.12.005.
J. W. Gichoya et al., “AI recognition of patient race in medical imaging: a modelling study,” Lancet Digit. Heal., vol. 4, no. 6, pp. e406–e414, 2022, doi: 10.1016/S2589-7500(22)00063-2.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Fitrah Karimah, Amirah
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
